Q3 25 EPS
$1.34
BEAT +9.59%
Est. $1.22
Q3 25 Revenue
$2.42B
MISS 3.71%
Est. $2.51B
vs S&P Since Q3 25
+11.3%
BEATING MARKET
CE +22.3% vs S&P +11.0%
Market Reaction
Did CE Beat Earnings? Q3 2025 Results
Celanese delivered a mixed Q3 2025, posting adjusted EPS of $1.34 against a consensus estimate of $1.22, a beat of 9.59%, even as revenue of $2.42 billion fell short of the $2.51 billion analysts expected and declined 8.7% year-over-year amid persist… Read more Celanese delivered a mixed Q3 2025, posting adjusted EPS of $1.34 against a consensus estimate of $1.22, a beat of 9.59%, even as revenue of $2.42 billion fell short of the $2.51 billion analysts expected and declined 8.7% year-over-year amid persistent demand weakness across most end-markets. The headline GAAP results were dominated by $1.49 billion in non-cash asset impairment charges, including significant goodwill and trade name writedowns in the Engineered Materials segment, underscoring the difficult operating environment the specialty chemicals maker continues to navigate. A standout bright spot was free cash flow of $375 million, a sharp recovery from negative free cash flow in the year-ago period, fueled by cost reductions and inventory drawdowns. The company also signed a definitive agreement to divest its Micromax® portfolio for approximately $500 million, with proceeds earmarked for debt reduction. Looking ahead, management guided Q4 adjusted EPS to $0.85 to $1.00, reflecting typical western hemisphere seasonality, while targeting full-year 2025 free cash flow of $700 million to $800 million as deleveraging remains the central strategic priority.
Key Takeaways
- • Cost reduction programs targeting discretionary spend, SG&A, and logistics/distribution
- • Product mix enrichment through High Impact Programs (HIPs) emphasizing specialty offerings
- • Inventory reduction of approximately $100 million targeted in Engineered Materials for 2025
- • Production optimization at low-cost U.S. based assets with reduced operating rates at higher cost sites
CE YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
CE Revenue by Segment
With YoY comparisons, source: SEC Filings
“Our strong third quarter free cash flow and Micromax® divestiture announcement clearly demonstrate that we are executing against our strategic action plans. Our third quarter free cash flow performance is a substantial improvement over the same period last year and shows the robust cash generation capabilities we have and continue to utilize. The signing of the Micromax® divestiture demonstrates our commitment to aggressively and prudently taking steps to deleverage our balance sheet. I thank our teams for their tenacity and resilience in driving these outcomes.”
— Scott Richardson, Q3 2025 Earnings Press Release
CE Earnings Trends
CE vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
CE EPS Trend
Earnings per share: estimate vs actual
CE Revenue Trend
Quarterly revenue: estimate vs actual
CE Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 MISS | $0.88 | $0.85 | -3.61% | $2.34B | -0.41% |
| Q4 25 MISS FY | $0.91 | $0.67 | -26.37% | $2.20B | -2.02% |
| FY Full Year | $4.25 | $3.98 | -6.42% | $9.54B | -0.41% |
| Q3 25 BEAT | $1.22 | $1.34 | +9.59% | $2.42B | -3.71% |
| Q2 25 BEAT | $1.40 | $1.44 | +2.82% | $2.53B | +1.89% |
| Q1 25 BEAT | $0.39 | $0.57 | +47.82% | $2.39B | +5.54% |